ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

Zacks Investment Research • Oct 28, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.

Zacks Investment Research • Oct 26, 2026

Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million

Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.

24/7 Wall Street • Oct 20, 2026

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Market Watch • Oct 15, 2026

From Laggard to Leader: The Surprising Comeback of Healthcare

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

ETF Trends • Oct 13, 2026

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

ETF Trends • Oct 12, 2026

Pharmaceutical trade group sues Trump administration

Pharmaceutical Research and ​Manufacturers of ‌America, the pharmaceutical ​industry lobbying ​group, sued the ⁠Trump ​administration on Wednesday, ​court records show.

Reuters • Oct 7, 2026

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

CNBC Television • Oct 6, 2026

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF experienced a much deeper maximum drawdown over the last five years but outperformed on a 1-year total return basis.

The Motley Fool • Oct 5, 2026

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals

The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited significantly lower price volatility and a smaller maximum drawdown than its biotech counterpart.

The Motley Fool • Oct 4, 2026